by Dennis Weissman & Associates, LLC | Mar 1, 2019 | Clinical Laboratory
In enacting the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) late last year, the U.S. Congress approved an unprecedented expansion of federal anti-kickback authority. EKRA adds an all payor anti-kickback rule to the health care fraud law concerning improper...
by Dennis Weissman & Associates, LLC | Dec 31, 2018 | Hospital Laboratories
Hospital outreach laboratories which escaped providing private payor data to Uncle Sam under The Protecting Access to Medicare Act (PAMA) during the first round of reporting in 2016 have now run out of luck as the next collection period starts this January and runs...
by Dennis Weissman & Associates, LLC | Nov 26, 2018 | Healthcare
Far more aggressive than anything they expected to see from a Republican Administration, the pharmaceutical industry was blindsided by a proposal by the Trump White House to import some of the price controls imposed by Europe’s single-payer healthcare systems. But...
by Dennis Weissman & Associates, LLC | Nov 16, 2018 | Clinical Laboratory, Hospital Laboratories
Starting next year, U.S. clinical laboratories including hospital outreach labs are facing a number of significant challenges now that the Centers for Medicare & Medicaid Services has made a significant change in its new market-based pricing system (PAMA) that...
by Dennis Weissman & Associates, LLC | Oct 1, 2018 | Affordable Care Act
Don’t look now but the upcoming 2018 U.S. midterm elections are shaping up as virtually the exact inverse of 2010 when widespread opposition to the Affordable Care Act (ACA) helped sweep Republicans into power from the local courthouse all the way up the...
